Prospective study of definitive chemoradiotherapy with S-1 and nedaplatin in patients with stage II/III (non-T4) esophageal cancer
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Takashi Tsuda Hiroyuki Inaba Aya Miyazaki Naoki Izawa Mami Hirakawa Yoshiyuki Watanabe Satoshi Kitajima Yoshikazu Hoshikawa Hiromichi
- چاپ و سال / کشور: 2010
Description
Background Standard chemoradiotherapy (CRT) using 5-FU and CDDP is the optimal treatment for patients with stage II/III (non-T4) esophageal carcinoma. However, patient quality of life (QOL) cannot necessarily be maintained during this therapy, because 5-FU must be continuously infused for 24 h and CDDP administration requires a large transfusion volume. Therefore, hospitalization is unavoidable. We conducted a study of definitive CRT with S-1 and nedaplatin. Methods The study was conducted between July 2004 and December 2006. Eligibility criteria were stage II/III (non-T4), PS 0–2, age 20–79 years, and adequate organ function. S-1 80 mg/m2 was given on days 1–14, and nedaplatin 90 mg/m2 on day 1 every 4 weeks. Patients received two courses with concurrent radiotherapy of more than 50 Gy. Results Twenty patients (age range, 50–75 years; PS 0/1, 8/12; stage IIA/IIB/III, 11/2/7) were enrolled. Grade 4 leukopenia, thrombocytopenia, and anemia occurred in 15%, 10%, and 5% of patients, respectively. Grade 3 nonhematotoxicity included esophagitis in 3 patients (15%) and anorexia in 2 (10%). One patient developed febrile neutropenia; another developed an esophageal fistula. Complete response was achieved in 80%. The 3-year overall survival rate was 58.0%. Thirteen subjects received treatment as outpatients. Conclusions S-1 and nedaplatin in combination with radiotherapy is feasible, and toxicity is tolerable. This treatment method has the potential to shorten hospitalization and maintain patient QOL without impairing the efficacy of CRT.
Esophagus (2011) 8:45–51 DOI 10.1007/s10388-011-0261-0 Received: 26 March 2010 / Accepted: 21 December 2010 / Published online: 15 February 2011
